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Disparity in outcomes for adult Native American hemodialysis
patients? Findings from the ESRD Clinical Performance Mea-
sures Project, 1996 to 1999.
Background. There is a paucity of information regarding the
quality of care for Native American hemodialysis patients. Out-
comes, including 1-year hospitalization and mortality, for adult
Native American in-center hemodialysis patients selected for
the Centers for Medicare & Medicaid (CMS) end-stage renal
disease (ESRD) Clinical Performance Measures (CPM) Project
were compared to those for white and black patients to deter-
mine if disparity in care existed for this group.
Methods Clinical data were abstracted from medical records
for the last quarters of 1995 to 1998 and linked to United States
Renal Data System (USRDS) data files for data on comorbidi-
ties and 1-year hospitalization and mortality. Associations of
race were tested by bivariate analyses and multivariate logistic
regression and Cox proportional hazard modeling.
Results. Two percent (467 of 27876) of patients were Native
American, 37% black, and 51% white. Native American, com-
pared to black and white patients, were more likely to have
diabetes mellitus as the cause of ESRD (72%, 37%, and 38%,
respectively, P < 0.01). In multivariate analyses, Native Ameri-
can patients were more likely to achieve a mean urea reduction
ratio (URR) ≥ 65% compared to whites (referent) [hazards
ratio (HR) (95% CI) 1.7 (1.3, 2.2)] and be dialyzed with an
arteriovenous fistula [HR (95% CI) 1.7 (1.2, 2.5)]. They were
as likely as Whites to achieve a mean hematocrit ≥33% and
a mean serum albumin ≥4.0/3.7 g/dL. In multivariate analyses,
Native Americans were no more likely to be hospitalized or die
during the follow-up period than whites.
Conclusion. These data suggest that adult Native American
hemodialysis patients experience equivalent or better dialytic
care and are no more likely to experience 1-year hospitalization
or mortality compared to whites.
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One of the goals of the federal government’s initia-
tive Healthy People 2010 is to eliminate health disparities
among different segments of the population [1]. In 2001,
adjusted point prevalent rates [per million population
(pmp)] of reported end-stage renal disease (ESRD) were
3540 pmp for Native Americans, 4432 pmp for blacks,
and 1004 pmp for whites [2]. Native Americans, defined
for this report as American Indians/Alaska Natives, have
an extraordinarily high prevalence of diabetes mellitus
compared to other racial groups [3–10]. As such, Native
Americans are at high risk for developing ESRD. Sev-
eral studies have suggested a genetic predisposition to
renal disease [11–14], and studies within Native Amer-
ican tribal groups have shown an increasing prevalence
of diabetes mellitus and renal disease as the degree of
Native American heritage increases [6, 10, 15]. Other
factors that have been implicated in possibly leading
to a higher prevalence of renal disease among minority
groups include lower socioeconomic status [15, 16] and
environmental toxins [17, 18].
Annually, the Centers for Medicare & Medicaid Ser-
vices (CMS) ESRD Clinical Performance Measures
(CPM) Project (formerly known as the ESRD Core In-
dicators Project) profiles certain intermediate outcomes
of care for nationally representative samples of adult
(≥18 years old) in-center hemodialysis patients. This
project assists dialysis care providers in identifying op-
portunities to improve care that may be due to action-
able practice differences [19, 20]. This project provides a
unique opportunity to determine if disparity in achiev-
ing different clinical outcomes exists for adult Native
American hemodialysis patients compared to other racial
groups from a nationally representative sample. This
study provides the first report of intermediate outcomes
from the ESRD CPM Project, 12-month follow-up all-
cause hospitalization and survival for Native American
adult in-center hemodialysis patients compared to white
and black patients.
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METHODS
Study design and sample selection
Detailed information about CMS’s ESRD CPM
Project has previously been published [21]. In brief, a
random sample, stratified by the 18 ESRD networks (re-
gional organizations contracted by CMS to perform qual-
ity oversight activities to assure the appropriateness of
services and protection for dialysis patients) of Medicare-
eligible adult in-center hemodialysis patients was selected
from an end-of-year ESRD patient census for the years
1995 to 1998 (ESRD CPM Project study years 1996 to
1999). Patients were eligible for inclusion in the sample if
they were at least 18 years old as of October 1 and were
receiving in-center hemodialysis and alive on December
31 of the census year. If a patient happened to be selected
for multiple samples during 1996 to 1999, only the data
from the first study year the patient was selected were
used for this study. Clinical information was obtained on
the selected patients for October through December of
the census year (i.e., for study year 1999, data were ab-
stracted for October to December 1998).
Administrative data from the United States Renal
Data System (USRDS) Hospitalization Standard Ana-
lytical File (SAF), Medical Evidence Form SAF, and the
Enrollment Database (EDB) were linked to the clinical
data from the ESRD CPM data for the sampled patients.
Preexisting comorbidities were obtained from the Med-
ical Evidence Form SAF that contains information from
CMS’s 2728 Form. Patients were classified as having ei-
ther no hospitalizations or one or more hospitalizations
during the 12-month follow-up period from the claims
data in the Hospitalization SAF. Dates of death were ob-
tained from the EDB.
Data collection
Each study year, the ESRD networks sent a three-page
data collection form to all facilities in the geographic
region with one or more patients selected for the sam-
ple. Available patient information included gender, age,
race (American Indian/Alaska Native, Asian/Pacific Is-
lander, black, white, and other/unknown), Hispanic eth-
nicity (collected for study years 1997 to 1999 only), the
primary cause of ESRD, and years on dialysis therapy. Fa-
cility staff verified this patient characteristic information
and corrected items if needed.
Clinical data were abstracted from medical records by
the dialysis facility staff for each month of the study peri-
ods and included the first documented pre- and postdialy-
sis patient blood urea nitrogen (BUN) values to calculate
urea reduction ratios (URRs), delivered dialysis session
length, hematocrit, prescribed weekly epoetin alfa dose
at the time the hematocrit was drawn, and serum albumin
with the laboratory method used to determine the serum
albumin [bromcresol green (BCG) or bromcresol pur-
ple (BCP)]. Information collected for study years 1997 to
1999 only included patient height, pre- and postdialysis
patient weights, dialyzer code (used to determine dialyzer
KUf), prescribed route of epoetin alfa administration,
transferrin saturation, serum ferritin concentration, and
iron prescription practice. Type of vascular access was
collected for study year 1999 only.
Data analyses
Outcomes for Native American patients were com-
pared to black and white patients only due to small
numbers in the other racial groups. Comorbidities
were collapsed into cardiovascular and noncardiovas-
cular causes for subsequent analyses. Cardiovascular
causes included cardiac arrest, congestive heart failure,
cerebrovascular disease, cardiac dysrhythmia, pericardi-
tis, peripheral vascular disease, ischemic heart disease,
and myocardial infarction. Noncardiovascular causes in-
cluded alcohol dependence, cancer, drug dependence,
human immunodeficiency virus (HIV), acquired immun-
odeficiency syndrome (AIDS), inability to ambulate, in-
ability to transfer, chronic obstructive pulmonary disease,
tobacco use, diabetes, currently on insulin, and diabetes
mellitus, primary or contributing. Associations of group
classification with the clinical data were tested by chi
square, hierarchic analysis of variance (ANOVA), and
two-tailed Student t test analyses. A P value < 0.05 for dif-
ferences among racial groups was considered to be signifi-
cant. Multivariate logistic regression analyses controlling
for patient characteristics were conducted for selected
intermediate outcomes (mean URR ≥ 65%, use of an
arteriovenousfistula, mean hematocrit ≥33%, and mean
serum albumin ≥4.0/3.7 g/dL (BCG/BCP).
Separate multivariate Cox proportional hazard mod-
els were developed to determine significant predic-
tors of all-cause hospitalization or mortality during the
12-month follow-up period. Patients were censored if
they were transplanted, switched to peritoneal dialysis,
or were lost to follow-up during the 12-month follow-up
period. All factors found to be significantly associated
with the outcomes of interest (all-cause hospitalizations
or mortality) or considered conceptually important were
entered simultaneously into separate Cox proportional
hazard models. Separate models were developed for all
patients and stratified by cause of ESRD (diabetes mel-
litus vs. other causes combined). Both forward stepwise
and backward stepwise modeling techniques were em-
ployed, utilizing the likelihood ratio statistic. Predictors
with a P value < 0.05 were retained in the final adjusted
models.
The data analyses were conducted utilizing SPSS for
Windows, Release 10.0 [22] and SAS version 8.02 (SAS
Institute, Cary, NC, USA).
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Table 1. Patient characteristics, by race, 1996 to 1999
Native
American Black White
Patient characteristic (N = 467) (N = 10,359) (N = 14,338)
% Femalea 56 50 45
% Hispanica 4 1 14
Age years
Mean (±SD)a 58.1 (±13.1) 57.3 (±14.7) 63.0 (±15.2)
Median 59.0 58.6 66.2
Cause of end-stage renal disease (ESRD)
% Diabetes mellitusa 72 37 38
% Hypertensiona 6 38 21
% Glomerulonephritisa 10 11 14
Duration of dialysis years
Mean (±SD)a 3.23 (±3.18) 3.80 (±3.85) 3.13 (±3.73)
Median 2.12 2.57 1.88
Postdialysis body mass index (BMI) kg/m2
Mean (±SD)a 26.1 (±5.8) 26.5 (±6.8) 25.5 (±6.4)
Median 25.3 25.1 24.4
aP < 0.001, denotes significant differences among racial groups.
RESULTS
Two percent (467/27,876) of patients were Native
American, 37% (10,359) were black, and 51% (14,338)
were white. Native American patients, compared to black
and white patients, were more likely to be female (56%
vs. 50% and 45%, respectively, P < 0.001), have diabetes
mellitus as the primary cause of ESRD (72% vs. 37%
and 38%, P < 0.001), and were less likely to have hy-
pertension as the primary cause of ESRD (6% vs. 38%
and 21%, P < 0.001) (Table 1). Age, duration of dialysis
(years), and postdialysis body mass index (BMI) (kg/m2)
for Native Americans were intermediate to black and
white patients. The distribution of Native American pa-
tients ranged from 0.6% to 47% among the 18 ESRD
networks. Approximately three fourths received their
dialysis care in three networks: 47% in Network 15
(Arizona, Colorado, New Mexico, Nevada, Utah, and
Wyoming), 14% in Network 16 (Alaska, Idaho, Montana,
Oregon, and Washington), and another 11% in Network
13 (Arkansas, Louisiana, and Oklahoma). The distribu-
tion of Native American patients in the sample closely
mirrored that reported in the United States 2000 Census
[23].
For the Cox proportional hazard models, 2222 patients
were censored. 952 patients were censored due to re-
ceiving a renal transplant, 195 changed modality from
hemodialysis to peritoneal dialysis, and another 1075 pa-
tients were lost to follow-up during the 12-month follow-
up period.
Pre-existing comorbidities
Native Americans were more likely to have “diabetes,
primary or contributing” reported as a comorbidity than
blacks or whites (65% vs. 39% and 39%, respectively, P <
0.001) and were more likely to have “diabetes, currently
on insulin” reported (34% vs. 22% and 24%, P < 0.001).
Native Americans and blacks were more likely to have
a history of hypertension reported than whites (75% vs.
79% and 73%, P < 0.001). Alcohol dependence was re-
ported for 6% of Native American patients, 3% of blacks,
and 1% of whites (P < 0.001). Cardiovascular comorbidi-
ties were reported for 50% of Native American patients,
41% of blacks, and 55% of whites (P < 0.001). Noncardio-
vascular comorbidities were reported for 75% of Native
American patients, 56% of blacks, and 57% of whites
(P < 0.001).
Intermediate outcomes
Native American patients had higher mean URR val-
ues compared to blacks and whites [70.1% (±8.2%)
vs. 67.0% (±7.9%) and 68.5% (±8.0), respectively,
P < 0.001] and a higher percentage achieved a mean
URR ≥ 65%, the National Kidney Foundation’s Dial-
ysis Outcomes Quality Initiative (NKF-DOQI) recom-
mended threshold for adequate dialysis [24], (79% vs.
67% and 73%, P < 0.001) (Table 2). Dialysis session
length was intermediate to that for black and white pa-
tients [207 (±30) minutes vs. 213 (±31) and 206 (±31)
minutes, P < 0.001]. A higher percentage of Native Amer-
ican patients were dialyzed with a high-flux dialyzer (de-
fined as ≥20 mL/mm Hg/hour) compared to black and
white patients (55% vs. 48% and 48%, P < 0.01).
NKF-DOQI guidelines recommend that at least 40%
of prevalent hemodialysis patients have an arteriovenous
fistula as their vascular access [25]. A higher percentage
of Native American patients were dialyzed with an arte-
riovenous fistula compared to black and white patients
(39% vs. 23% and 29%, P < 0.001). Native American
patients were less likely to be dialyzed with either an ar-
teriovenous graft (44% vs. 59% and 49%, P < 0.001) or
a catheter (17% vs. 18% and 22%, P < 0.001).
Native American patients achieved a slightly higher
mean hematocrit compared to black and white patients
[33.5 (±3.8)% vs. 32.9 (±4.1)% and 33.2 (±3.6)%, P <
0.001]; 54% of Native American patients had a mean
hematocrit ≥33% compared to 52% of black and 55%
of white patients (P < 0.001). Approximately 95% of
patients in all three groups were prescribed epoetin
alfa. Native American patients were prescribed signifi-
cantly lower weekly intravenous epoetin alfa doses [186
(±150) units/kg/week vs. 214 (±161) and 208 (±153)
units/kg/week, P < 0.01]. Native American patients
demonstrated a lower epoetin alfa resistance as suggested
by the lower median weekly epoetin alfa dose per hemat-
ocrit per kg body weight compared to black and white pa-
tients (4.19 weekly dose/hematocrit/kg compared to 5.21
and 5.02 weekly dose/hematocrit/kg, respectively).
Transferrin saturation and serum ferritin concentra-
tions for Native American patients were equivalent or
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Table 2. Intermediate outcomes, by race, 1996 to 1999
Native
American Black White
Clinical Measurea (N = 467) (N = 10,359) (N = 14,338)
Dialysis adequacy
Urea reduction ratio %
Mean (±SD)b 70.1 (±8.2) 67.0 (±7.9) 68.5 (±8.0)
Median 70.9 68.0 69.4
% With mean urea reduction ratio ≥ 65%b 79 67 73
Dialysis session length minutes
Mean (±SD)b 207 (±30) 213 (±31) 206 (±31)
Median 210 210 210
% Hi-flux dialyzerc ≥ 20 mL/mm Hg/hour 55 48 48
Vascular accessd
% Arteriovenous fistulab 39 23 29
% Arteriovenous graftb 44 59 49
% Catheterb 17 18 22
% Chronic catheter usee 15 13 17
Anemia management
Hematocrit%
Mean (±SD)b 33.5 (±3.8) 32.9 (±4.1) 33.2 (±3.6)
Median 33.3 33.1 33.4
% Hematocrit < 30%b 17 21 17
% Hematocrit ≥ 33%b 54 52 55
% Prescribed epoetin alfa 95 96 95
Intravenouslyb 90 91 89
Subcutanouslyb 10 9 11
Weekly epoetin alfa dose units/kg/week
Intravenously
Mean (±SD)c 185.7 (±149.7) 214.3 (±161.2) 208.4 (±153.4)
Median 141.7 176.0 171.5
Subcutanously
Mean (±SD) 204.5 (±200.9) 191.8 (±145.1) 187.7 (±140.4)
Median 180.9 155.1 149.7
Transferrin saturation %
Mean (±SD)b 29.4 (±14.1) 29.4 (±14.9) 28.0 (±13.5)
Median 26.3 26.3 25.3
% Transferrin saturation ≥ 20%b 76 76 73
Serum ferritin concentration ng/mL
Mean (±SD)b 514.6 (±402.2) 457.5 (±393.5) 424.4 (±376.4)
Median 436.3 356.0 314.5
% Serum ferritin concentration
≥100 ng/mLb 85 84 82
% Serum ferritin concentration
>800 ng/mLb 21 17 15
% Iron deficientf 6 6 7
% Prescribed irong 52 57 55
Intravenouslyc 86 76 76
Orallyb 26 41 39
Serum albumin
Serum albumin g/dL
Bromcresol green (BCG) method
Mean (±SD)b 3.72 (±0.47) 3.83 (±0.42) 3.79 (±0.43)
Median 3.77 3.87 3.80
Bromcresol purple (BCP) method
Mean (±SD)b 3.47 (±0.43) 3.64 (±0.52) 3.54 (±0.47)
Median 3.50 3.67 3.53
% Mean serum albumin g/dL
≥4.0/3.7 g/dL (BCG/BCP)b 30 38 33
≥3.5/3.2 g/dL (BCG/BCP)b 76 84 81
aContinuous variables displayed as the mean (±SD) ad median values; categorical variables displayed as percent of available values.
bP < 0.001, denotes significant differences among racial groups.
cP < 0.01, denotes significant differences among racial groups.
dVascular access information collected only in study year 1999.
eChronic catheter use defined as continuous use of a catheter for 90 days or longer.
fIron deficiency defined for this report as a mean transferrin saturation <20% and a mean serum ferritin concentration < 100 ng/mL.
gP < 0.05, denotes significant differences among racial groups.
1430 Frankenfield et al: Disparity in outcomes for adult Native American hemodialysis patients
Table 3. Final multivariate logistic regression models predicting selected intermediate outcomes, by race, 1996 to 1999
Serum albumin
Urea reduction Arteriovenous ≥ 4.0/3.7 g/dL
ratio ≥ 65% fistula use Hematocrit ≥ 33% (BCG/BCP)
Patient characteristic OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Race (white as referent)
Native American 1.7 (1.3, 2.2)a 1.7 (1.2, 2.5)b 1.1 (0.88, 1.4) 0.98 (0.77, 1.3)
Black 0.69 (0.65, 0.73)a 0.63 (0.56, 0.71)a 0.91 (0.85, 0.97)b 1.2 (1.1, 1.3)a
Male gender 0.38 (0.36, 0.41)a 2.7 (2.4, 3.0)a 1.25 (1.18, 1.33)a 1.7 (1.6, 1.8)a
Hispanic ethnicity NS NS 1.14 (1.02, 1.28)c 1.2 (1.1, 1.4)a
Age years 1.016 (1.014, 1.018)a 0.9814 (0.9778, 0.9851)a 1.007 (1.005, 1.009)a 0.9788 (0.9767, 0.9809)a
Diabetes mellitus as cause of end-stage 0.79 (0.75, 0.84)a 0.76 (0.68, 0.86)a NS 0.67 (0.62, 0.71)a
renal disease (ESRD) (other causes
combined as referent)
Duration of dialysis (<0.5 years as referent) years
0.5–0.9 2.2 (2.0, 2.5)a 1.5 (1.2, 1.9)a 2.2 (2.0, 2.5)a 2.0 (1.7, 2.2)a
1.0–1.9 2.9 (2.6, 3.2)a 1.6 (1.3, 1.9)a 2.3 (2.0, 2.5)a 2.5 (2.2, 2.8)a
2.0+ 3.8 (3.4, 4.1)a 1.6 (1.3, 1.9)a 2.3 (2.1, 2.5)a 2.6 (2.3, 2.9)a
aP < 0.001; bP < 0.01; cP < 0.05.
NS is not significant.
higher than for black or white patients. Approximately
55% of patients in each group were prescribed some iron
during the study period. Within the subset of patients pre-
scribed iron, Native American patients were more likely
to have intravenous iron prescribed (86% vs. 76% and
76%, P < 0.01).
Serum albumin values were significantly lower for Na-
tive American patients [BCG 3.7 (±0.5) g/dL vs. 3.8
(±0.4) and 3.8 (±0.4) g/dL, P < 0.001/BCP 3.5 (±0.4 g/
dL vs. 3.6 (±0.5) and 3.5 (±0.5) g/dL, P < 0.001]. In
unadjusted analysis, Native American patients were less
likely to reach the target serum albumin ≥ 4.0/3.7 g/dL
BCG/BCP (30% vs. 38% and 33%, P < 0.001).
In multivariate logistic regression analysis, Native
American patients were significantly more likely to
achieve a mean URR≥65% compared to black and white
patients [odds ratio (OR) (95% CI) Native Americans 1.7
(1.3, 2.2) vs. blacks 0.69 (0.65, 0.73), whites = referent],
and more likely to be dialyzed with an arteriovenous fis-
tula [Native Americans 1.7 (1.2, 2.5) vs. blacks 0.63 (0.56,
0.71), whites = referent] (Table 3). They were as likely as
whites to achieve a mean hematocrit ≥ 33% and a mean
serum albumin ≥ 4.0/3.7 g/dL.
ESRD network subanalyses
A comparison of outcomes for Native American pa-
tients compared to white and black patients was con-
ducted for the three ESRD networks with the highest
percentages of Native American patients in their region:
Networks 13, 15, and 16 (N = 333 or 72% of Native Amer-
icans in the sample). In bivariate analyses, similar to the
national patterns, Native American patients tended to
experience equivalent or better intermediate outcomes
compared to white or black patients within their geo-
graphic region. They had higher mean URRs, equivalent
mean hematocrits, equivalent or better iron stores, and
a higher percentage was dialyzed with an arteriovenous
fistula. Also similar to national patterns, within these net-
works, Native American patients tended to have lower
mean serum albumin levels and fewer met the differ-
ent targets for serum albumin levels (≥4.0/3.7 g/dL or
≥3.5/3.2 g/dL, BCG/BCP).
Intermediate outcomes for patients receiving dialytic
care in Networks 13, 15, and 16 were compared to those
experienced by patients receiving care in all other net-
works. Patients in Networks 13, 15, and 16 compared
to patients in all other networks tended to be better
dialyzed [mean URR 68.4 (±8.0)% vs. 67.9 (±8.0)%,
respectively, P < 0.01], were more likely to have an arte-
riovenous fistula as their vascular access (30% vs. 27%,
P < 0.05), had higher mean hematocrits [33.3 (±3.8)%
vs. 33.1 (±3.8)%, P < 0.01], were prescribed lower mean
intravenous epoetin doses [194 (±150) units/kg/week vs.
214 (±159) units/kg/week, P < 0.001], were more likely
to be prescribed intravenous iron (84% vs. 74%, P <
0.001), and had lower mean serum albumin values by ei-
ther laboratory method [BCG 3.78 (±0.41) g/dL vs. 3.81
(±0.43) g/dL, P < 0.001; BCP 3.49 (±0.43) g/dL vs. 3.59
(±0.50) g/dL, P < 0.001].
All-cause hospitalization during the 12-month
follow-up period
Fifty-six percent (262/467) of Native American patients
had one or more all-cause hospitalizations during the
12-month follow-up period, as did 56% (5843/10359) of
black patients and 59% (8468/14338) of white patients
(P < 0.001). Unadjusted risks [hazard ratio (HR), 95%
CI] for all-cause hospitalization during the 12-month
follow-up period for Native American and black pa-
tients, compared to whites (the referent group) were 0.92
(0.81, 1.04), P = 0.1972 and 0.93 (0.90, 0.96), P < 0.001,
respectively. In multivariate Cox proportional hazard
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Table 4. Final multivariate Cox proportional hazard model predicting all-cause hospitalization during the 12-month follow-up period for adult
Native American hemodialysis patients, by cause of end-stage renal disease (ESRD), 1996 to 1999
Diabetes mellitus
All as cause of ESRD Other causes combined
Characteristic Hazard ratio P value Hazard ratio P value Hazard ratio P value
Race (white as referent)
Native American 1.1 (0.81, 1.4) 0.6272a 1.1 (0.77, 1.4) 0.7418a 0.82 (0.44, 1.5) 0.5232a
Black 1.03 (0.94, 1.1) 0.4942 0.97 (0.85, 1.1) 0.6326 1.1 (0.95, 1.2) 0.2442
Male gender NS NS NS
Hispanic ethnicity NS 0.76 (0.61, 0.95) <0.05 NS
Increasing age years 1.0082 (1.0051, 1.0114) <0.001 NS 1.0113 (1.0073, 1.0153) <0.001
Diabetes mellitus as cause of ESRD 1.15 (1.06, 1.26) <0.01 NE NE
(other causes combined as referent)
Duration of dialysis (≥6 months as referent)
<6 months 0.74 (0.66, 0.83) <0.001 0.73 (0.62, 0.86) <0.001 0.76 (0.65, 0.89) <0.001
Mean postdialysis
Body mass index kg/m2 NS NS
quartile [highest quartile
(>28.8) as referent]
1 (<21.5) 1.2 (1.04, 1.3) <0.05
2 (21.5–24.6) 1.03 (0.92, 1.2) 0.6592
3 (24.7–28.8) 1.07 (0.95, 1.2) 0.2771
Cardiovascular comorbidities 1.2 (1.1, 1.3) <0.001 1.2 (1.02, 1.3) <0.05 1.2 (1.1, 1.4) <0.001
Noncardiovascular comorbidities NS NS 1.2 (1.1, 1.3) <0.01
Mean serum albumin <3.5/3.2 g/dL 1.2 (1.1, 1.3) <0.001 1.2 (1.1, 1.4) <0.01 NS
(bromcresol green/bromcresol
purple methods)
Mean hematocrit <33% 1.2 (1.1, 1.3) <0.001 1.2 (1.1, 1.4) <0.01 1.2 (1.1, 1.4) <0.01
Catheter use 1.3 (1.2, 1.5) <0.001 1.5 (1.3, 1.7) <0.001 1.3 (1.1, 1.5) <0.001
Mean urea reduction ratio <65% NS NS NS
aRace forced into the final model.
NS is not significant and NE is not entered into the model.
modeling, Native Americans and blacks were no more
likely to be hospitalized during the follow-up period than
whites (Table 4). This finding also applied to patients with
diabetes mellitus as the cause of ESRD and for patients
with other causes combined. Factors significantly pre-
dicting hospitalization for all patients during the follow-
up period, included increasing age, diabetes mellitus as
the cause of ESRD, more years on dialysis, lowest quar-
tile of mean postdialysis BMI, preexisting cardiovascu-
lar comorbidities, mean serum albumin <3.5/3.2 g/dL
(BCG/BCP), mean hematocrit <33%, and catheter use
(Table 4).
Mortality during the 12-month follow-up period
Nineteen percent (89/467) of Native American patients
died during the 12-month follow-up period, as did 15%
(1585/10359) and 24% (3373/14338) of black and white
patients, respectively (P < 0.001). Unadjusted risks of
mortality during the 12-month follow-up period for Na-
tive American and black patients compared to whites (the
referent group) were 0.79 (0.64, 0.97), P < 0.05 and 0.61
(0.57, 0.65), P < 0.001, respectively. In multivariate Cox
proportional hazard modeling, Native American patients
were no more likely to die during the follow-up period
than whites [HR (95% CI) 1.1 (0.70, 1.6), P = 0.7553],
but black patients were less likely to die compared to
white patients [HR (95% CI) 0.72 (0.62, 0.83), P < 0.001]
(Table 5). This pattern was also present for the subset
of patients with diabetes mellitus as the cause of ESRD;
however, among those patients with other causes com-
bined, Native Americans and blacks were no more likely
to die during the follow-up period than whites. Factors sig-
nificantly associated with mortality for all patients during
the 12-month follow-up period included increasing age,
diabetes mellitus as the cause of ESRD, more years on
dialysis, lower mean postdialysis BMI, preexisting car-
diovascular comorbidities, mean serum albumin <3.5/3.2
g/dL (BCG/BCP), mean hematocrit <33%, and catheter
use (Table 5).
DISCUSSION
In United States Census 2000, 2.5 million (0.9%) of
respondents reported that they were American Indian
and/or Alaska Native [23]. This race is one of the fastest
growing groups in the United States, with an increase be-
tween 1990 and 2000 of 26% compared to 13% for the to-
tal population. This growth may be due, in part, to changes
in self-identification over this time period. Native Amer-
icans comprise a heterogeneous group, with membership
in approximately 550 federally recognized tribes [6, 26].
Although there have been several reports describing di-
abetes mellitus and/or ESRD in Native Americans, these
reports have examined tribal or regional data [7–10, 15,
17, 18, 27–37]. We are not aware of any previous reports
describing outcomes for Native American hemodialysis
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Table 5. Final multivariate Cox proportional hazard model predicting mortality during the 12-month follow-up period for adult Native American
hemodialysis patients, 1996 to 1999
Diabetes as cause of end-stage
All renal disease (ESRD) Other causes combined
Characteristic Hazard ratio P value Hazard ratio P value Hazard ratio P value
Race (white as referent)
Native American 1.1 (0.70, 1.6) 0.7553 1.2 (0.81, 1.7) 0.3885 0.23 (0.03, 1.6) 0.1396a
Black 0.72 (0.62, 0.83) <0.001 0.68 (0.57, 0.81) <0.001 0.84 (0.68, 1.04) 0.1098
Male gender NS NS NS
Hispanic ethnicity NS NS NS
Increasing age years 1.0293 (1.0238, 1.0348) <0.001 1.0305 (1.0231, 1.0378) <0.001 1.0273 (1.0200, 1.0347) <0.001
Diabetes mellitus as cause of ESRD 1.4 (1.3, 1.6) <0.001 NE NE
(other causes combined as referent)
Duration of dialysis (≥6 months as referent)
< 6 months 0.61 (0.51, 0.72) <0.001 0.55 (0.44, 0.70) <0.001 0.61 (0.48, 0.79) <0.001
Mean postdialysis
Body mass index (BMI) kg/m2
quartile [highest quartile
(>28.8) as referent]
1 (<21.5) 1.7 (1.4, 2.0) <0.001 1.5 (1.2, 1.9) <0.001 1.7 (1.2, 2.3) <0.001
2 (21.5–24.6) 1.5 (1.2, 1.8) <0.001 1.1 (0.89, 1.4) 0.3673 1.9 (1.4, 2.6) <0.001
3 (24.7–28.8) 1.2 (0.97, 1.4) 0.0906 1.3 (1.1, 1.6) <0.01 1.05 (0.75, 1.5) 0.7659
Cardiovascular comorbidities 1.2 (1.03, 1.4) <0.05 NS 1.3 (1.1, 1.6) <0.01
Noncardiovascular comorbidities NS NS 1.3 (1.1, 1.5) <0.05
Mean serum albumin <3.5/3.2 g/dL 1.8 (1.6, 2.1) <0.001 1.8 (1.5, 2.2) <0.001 1.8 (1.4, 2.2) <0.001
(bromcresol green/bromcresol
purple methods)
Mean hematocrit <33% 1.3 (1.2, 1.5) <0.001 1.2 (1.04, 1.5) <0.05 1.4 (1.2, 1.7) <0.001
Catheter use 1.5 (1.3, 1.8) <0.001 1.6 (1.3, 1.9) <0.001 1.6 (1.3, 2.0) <0.001
Mean urea reduction ration <65% NS NS NS
aRace forced into the model.
NS is not significant and NE is not entered into the model.
Factors entered into the model but found to be nonsignificant included gender, Hispanic ethnicity, noncardiovascular comorbidities, and mean urea reduction ratio
≥65%.
patients from a nationally representative sample other
than an earlier unpublished report from this project [38].
The prevalence rate of diabetes mellitus in Native
Americans receiving hemodialysis was almost twice as
high as the prevalence rate of diabetes mellitus in either
black or white patients on chronic hemodialysis therapy.
Our finding of a strikingly high prevalence of diabetes
mellitus without regard to renal function among Native
American patients on hemodialysis therapy is similar to
previous reports for tribal/regional groups [8–10]. The
prevalence of diabetes mellitus also varies by tribal group,
with rates as high as 70% reported for members of tribal
groups in Arizona [31]. This disease was rare in this pop-
ulation prior to World War II, and its high prevalence
since that time has been attributed to an evolution of tra-
ditional diets with periods of feast and famine to a high
fat and low fiber diet provided at least in part by federal
government feeding programs, and to a more sedentary
lifestyle [17, 29, 39, 40]. This disease is increasingly ap-
pearing in younger age groups [3, 4, 34, 39, 41] and may
be expected to continue to contribute to the epidemic of
renal disease noted in this population.
Native Americans living on reservations face obstacles
to receiving quality health care, including poverty, living
in remote, isolated locations, a shortage of health care
providers in remote areas, and cultural and language bar-
riers between patient and provider [6, 26]. Approximately
61% of all persons identified as Native Americans in the
United States Census 2000 lived in urban areas [42]. This
subgroup lives within the general population and gener-
ally does not receive health care from the Indian Health
Service (IHS) due to funding constraints [26, 43]. Approx-
imately 40% of the Native American population does not
receive health care from the IHS [3, 4, 44]. One might ex-
pect that, for differing reasons, Native Americans living
either on the reservation or in urban areas might not ex-
perience equivalent outcomes compared to the majority
racial group. That Native American hemodialysis patients
in this data set experienced generally equivalent or bet-
ter intermediate outcomes related to dialytic care (dialy-
sis adequacy, anemia management, and vascular access)
compared to the majority racial group is encouraging, but
further study of larger numbers in this group is needed to
confirm the results obtained in this study.
In unadjusted analysis, Native American patients were
less likely to achieve serum albumin targets compared
to whites or blacks. This result is not surprising, since
patients with diabetes mellitus have lower serum albu-
min values than patients with other causes of renal dis-
ease [45]. Since the Native Americans in our sample had
a prevalence of diabetes mellitus that was almost twice
that for blacks or whites, it is not surprising that the serum
albumin values were lower in Native Americans. In mul-
tivariate analysis, adjusted for patient characteristics and
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clinical parameters, Native American patients were as
likely to achieve a mean serum albumin ≥4.0/3.7 g/dL as
whites.
We are aware of only one published study describ-
ing subsequent hospitalization or survival experience in-
cluding Native American hemodialysis patients. Lopes
et al [46] have reported health-related quality-of-life
(HRQOL) scores for various racial/ethnic groups, in-
cluding Native Americans (N = 50). HRQOL summary
measures were placed into multivariate Cox proportional
hazard models predicting either hospitalization or death.
The Native American group was collapsed into the cat-
egory “all groups” for the subsequent hospitalization
model, so there was no information regarding hospital-
ization for this racial group. The adjusted relative risk of
death for Native Americans in this study was 0.48 (0.32,
0.73, P < 0.001) compared to whites.
Native Americans in this sample were no more likely
to have subsequent all-cause hospitalization compared to
the majority racial group. This finding held for all Native
Americans, and for patients stratified by cause of ESRD
(diabetes mellitus vs. other causes combined). In the fi-
nal multivariate model for all patients, increasing age,
diabetes mellitus as the cause of ESRD, more years on
dialysis, lower BMI, cardiovascular comorbidities, lower
serum albumin and hematocrit, and catheter use were
significant predictors for 12-month all-cause hospitaliza-
tion. URR did not significantly predict this outcome for
all patients or for patients stratified by cause of ESRD.
Our finding of an intermediate mortality rate for Na-
tive American patients compared to whites and blacks
is similar to that reported by others [2, 47]. In our final
multivariate model, there was no significant difference
in 12-month survival for Native Americans compared to
whites. This finding differs from that of Lopes et al [46].
The final adjusted model in our study did not include so-
cioeconomic factors (i.e., yearly household income, edu-
cation, occupational status, or living status) or HRQOL
summary scores that were included in that study. Our
finding of a survival advantage for blacks compared to
whites is similar to previous reports [48, 49].
These data were cross-sectional, thus no causal asso-
ciations may be determined. There may have been some
racial misclassification, with an underestimation of Na-
tive Americans in the sample. Other investigators have
identified misclassification of Native Americans in ad-
ministrative data bases, so it is possible that some patients
may not have been correctly categorized [50–52]. Facility
staff had the opportunity to correct racial classification
on the ESRD CPM data collection form, so we believe
the extent of potential misclassification was minimal and
did not affect the results of our study. We did not have
information on tribal group for the Native American pa-
tients in our sample, thus we could not examine potential
differences among these groups. Degree of Native Amer-
ican heritage was not available, so we could not examine
the effect of this parameter on any outcome.
We noted significant regional variation in some inter-
mediate outcomes of care by ESRD Network area. We
did not have the ability to examine variation by other
regional definitions, such as IHS catchment areas, rural
vs. urban, IHS-delivered care vs. non-IHS-delivered care,
etc. Given the variation in care noted by ESRD network
area in this study, further research examining possible
variation by other regional definitions is needed to bet-
ter understand contributions to clinical outcomes experi-
enced by this minority group.
Another consideration is that hemodialysis practice
was changing over the four year study period. For ex-
ample, the clinical practice guidelines published by the
Renal Physicians Association were used by CMS during
the initial period of follow-up, and were replaced by the
NKF DOQI guidelines after their publication in 1997 [24,
25]. We are unaware, however, of any reason that these
changes should be expected to influence care among Na-
tive Americans in a manner different from other ESRD
patients.
Despite these limitations, to our knowledge, the results
presented in this report are the first to report interme-
diate outcomes and hospitalization and mortality experi-
ence for Native American in-center hemodialysis patients
from a large nationally representative data base. Further
and continual study is needed to more completely under-
stand the health care experience for this important and
rapidly growing population of ESRD patients to ensure
that disparity in outcomes is eliminated where it exists.
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